Epstein Barr Virus Positivity and Behavioral Patterns in Nasopharyngeal Cancer Patients Presenting in Oncology Ward at JPMC, Karachi
Epstein Barr Virus Positivity in Nasopharyngeal Cancer Patients
DOI:
https://doi.org/10.54393/pjhs.v5i12.2072Keywords:
Nasopharyngeal Cancer, Epstein-Barr Virus, Clinical Stage, Latent Membrane ProteinAbstract
Immunohistochemistry tests for the presence of the Epstein-Barr virus latent membrane protein (EBV-LMP), which can be used to diagnose non-Hodgkin's lymphoma. Tumors expressing high amounts of latent membrane protein 1 (LMP-1) provide more evidence that EBV is an etiologic agent in the development of non-Hodgkin lymphoma. Objective: To investigate the association between Epstein-Barr Virus infection and Nasopharyngeal Cancers within a cohort of 131 patients. Methods: A prospective, observational approach was employed, gathering demographic data, addiction profiles, clinical stages, histopathological types, and Epstein-Barr Virus status through patient interviews and medical records review. Polymerase chain reaction assisted in the detection of the Epstein Barr Virus in paraffin-embedded tissue slices that had been treated with formalin. Results: Among the participants, 92 (70.2%) tested positive for Epstein-Barr Virus infection. Notably, 49.6% of Epstein-Barr Virus-positive individuals were active smokers, and 64.9% were treatment-naive. Epstein-Barr Virus positivity was prevalent in stage II (40.5%) and stage III (35.1%) nasopharyngeal cancer patients. Conclusions: It was concluded that understanding the role of the Epstein-Barr Virus and associated risk factors in nasopharyngeal cancer development is crucial for targeted interventions and preventive measures. Further research could enhance our understanding of Epstein-Barr Virus-associated cancers and inform prospective intervention methods.
References
Salahuddin S, Khan J, Azhar J, Whitehurst CB, Qadri I, Shackelford J et al. Prevalence of Epstein–Barr Virus Genotypes in Pakistani Lymphoma Patients. Asian Pacific Journal of Cancer Prevention. 2018; 19(11): 3153. doi: 10.31557/APJCP.2018.19.11.3153. DOI: https://doi.org/10.31557/APJCP.2018.19.11.3153
Chan AT, Hui EP, Ngan RK, Tung SY, Cheng AC, Ng WT et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. Journal of Clinical Oncology. 2018 Nov; 36(31): 3091-100. doi: 10.1200/JCO.2018.77.7847. DOI: https://doi.org/10.1200/JCO.2018.77.7847
Salano VE, Mwakigonja AR, Abdulshakoor A, Kahinga AA, Richard EM. Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma. Journal of Global Oncology. 2021 Sep; 7: 1406-12. doi: 10.1200/GO.21.00120. DOI: https://doi.org/10.1200/GO.21.00120
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019; 394(1):64–80. doi: 10.1016/S0140-6736(19)30956-0 DOI: https://doi.org/10.1016/S0140-6736(19)30956-0
Tsang CM, Lui VW, Bruce JP, Pugh TJ, Lo KW. Translational Genomics of Nasopharyngeal Cancer. In Seminars in Cancer Biology. 2020 Apr; 61: 84-100. doi: 10.1016/j.semcancer.2019.09.006. DOI: https://doi.org/10.1016/j.semcancer.2019.09.006
Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus neoplasia. Am J Pathol. 1995;146(6):1355–1367.
Ayee R, Ofori ME, Tagoe EA, Languon S, Searyoh K, Armooh L et al. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana. Viruses. 2020 Jul; 12(7): 766. doi: 10.3390/v12070766. DOI: https://doi.org/10.3390/v12070766
Xuemei J, Weidong Z, Conghua X, Bicheng W, Gong Z, Fuxiang Z. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer. 2011;129(3):724–732.doi:10.1002/ijc.25696 DOI: https://doi.org/10.1002/ijc.25696
Ruuskanen M, Irjala H, Minn H, Vahlberg T, Randen‐Brady R, Hagström J et al. Epstein‐Barr Virus and Human Papillomaviruses as Favorable Prognostic Factors in Nasopharyngeal Carcinoma: A Nationwide Study in Finland. Head & Neck. 2019 Feb; 41(2): 349-57. doi: 10.1002/hed.25450 DOI: https://doi.org/10.1002/hed.25450
Rafiq F, Rehman A, Khan AA. Clinical Presentation of Nasopharyngeal Carcinoma Experience at ENT Department, Jinnah Hospital, Lahore. Headache. 2018 Jul; 15: 30.
Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM et al. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases. Journal of Virology. 2017 Nov; 91(21): 10-128. doi: 10.1128/JVI.00382-17. DOI: https://doi.org/10.1128/JVI.00382-17
Sharif SE, Zawawi N, Yajid AI, Shukri NM, Mohamad I. Pathology Classification of Nasopharyngeal Carcinoma. In an Evidence-Based Approach to the Management of Nasopharyngeal Cancer. 2020 Jan: 73-92. doi: 10.1016/B978-0-12-814403-9.00005-7. DOI: https://doi.org/10.1016/B978-0-12-814403-9.00005-7
Fierti AO, Yakass MB, Okertchiri EA, Adadey SM, Quaye O. The Role of Epstein-Barr Virus in Modulating Key Tumor Suppressor Genes in Associated Malignancies: Epigenetics, Transcriptional, And Post-Translational Modifications. Biomolecules. 2022 Jan; 12(1): 127. doi: 10.3390/biom12010127. DOI: https://doi.org/10.3390/biom12010127
Chan JY and Wong ST. The Role of Plasma Epstein‐Barr Virus DNA in the Management of Recurrent Nasopharyngeal Carcinoma. The Laryngoscope. 2014 Jan; 124(1): 126-30. doi: 10.1002/lary.24193. DOI: https://doi.org/10.1002/lary.24193
Su ZY, Siak PY, Leong CO, Cheah SC. The Role of Epstein–Barr Virus in Nasopharyngeal Carcinoma. Frontiers in Microbiology. 2023 Feb; 14: 1116143. doi: 10.3389/fmicb.2023.1116143. DOI: https://doi.org/10.3389/fmicb.2023.1116143
Wu L, Li C, Pan L. Nasopharyngeal Carcinoma: A Review of Current Updates. Experimental and Therapeutic Medicine. 2018 Apr; 15(4): 3687-92. doi: 10.3892/etm.2018.5878. DOI: https://doi.org/10.3892/etm.2018.5878
Vasudevan HN and Yom SS. Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus. Hematology/Oncology Clinics. 2021 Oct; 35(5): 963-71. doi: 10.1016/j.hoc.2021.05.007. DOI: https://doi.org/10.1016/j.hoc.2021.05.007
Al-Anazi AE, Alanazi BS, Alshanbari HM, Masuadi E, Hamed ME, Dandachi I et al. Increased Prevalence of EBV Infection in Nasopharyngeal Carcinoma Patients: A Six-Year Cross-Sectional Study. Cancers. 2023 Jan; 15(3): 643. doi: 10.3390/cancers15030643. DOI: https://doi.org/10.3390/cancers15030643
Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK et al. Targeting Epstein-Barr virus in Nasopharyngeal Carcinoma. Frontiers in Oncology. 2020 May; 10: 600. doi: 10.3389/fonc.2020.00600. DOI: https://doi.org/10.3389/fonc.2020.00600
Leong MM and Lung ML. The Impact of Epstein-Barr Virus Infection on Epigenetic Regulation of Host Cell Gene Expression in Epithelial and Lymphocytic Malignancies. Frontiers in Oncology. 2021 Feb; 11: 629780. doi: 10.3389/fonc.2021.629780. DOI: https://doi.org/10.3389/fonc.2021.629780
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
